Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5

Onishi, Rika; Ikemoto, Sena; Shiota, Aoi; Tsukamoto, Tomohito; Asayama, Akira; Tachibana, Masashi; Sakurai, Fuminori; Mizuguchi, Hiroyuki

doi:https://doi.org/10.1016/j.ijpharm.2024.124480

Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5

Onishi, Rika; Ikemoto, Sena; Shiota, Aoi et al.

International Journal of Pharmaceutics, 2024, 662, 124480

アクセス数:716件（2025-07-03 23:32 集計）

固定URL: https://hdl.handle.net/11094/98172

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
IntJPharm_662_124480	pdf	なし	2.30 MB	67	2024.09.27

Creative Commons : 表示 - 非営利 - 改変禁止

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5
著者	著者名 Onishi, Rika
	著者名 Ikemoto, Sena
	著者名 Shiota, Aoi
	NRID 1000020977342 1000020977342 researchmap permalink tsukamoto-t tsukamoto-t 著者名 Tsukamoto, Tomohito
	著者名 Asayama, Akira
	NRID 1000080513449 1000080513449 著者名 Tachibana, Masashi
	NRID 1000070370939 1000070370939 researchmap permalink read0165081 read0165081 Scopus Author ID 7003748169 7003748169 著者名 Sakurai, Fuminori
	NRID 1000050311387 1000050311387 researchmap permalink read0165079 read0165079 Scopus Author ID 57195381326 57195381326 著者名 Mizuguchi, Hiroyuki
キーワード等	Adenovirus vector
	Arg-Gly-Asn (RGD) peptide
	Fiber-mutant
	Vaccine
	αv-integrin
内容	Onishi R., Ikemoto S., Shiota A., et al. Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5. International Journal of Pharmaceutics 662, 124480 (2024); https://doi.org/10.1016/j.ijpharm.2024.124480.
抄録	Adenovirus (Ad) vectors based on human adenovirus serotype 5 (Ad5) have attracted significant attention as vaccine vectors for infectious diseases. However, the effectiveness of Ad5 vectors as vaccines is often inhibited by the anti-Ad5 neutralizing antibodies retained by many adults. To overcome this drawback, we focused on human adenovirus serotype 35 (Ad35) vectors with low seroprevalence in adults. Although Ad35 vectors can circumvent anti-Ad5 neutralizing antibodies, vector yields of Ad35 vectors are often inferior to those of Ad5 vectors. In this study, we developed novel Ad35 vectors containing the Ad5 E4 orf 4, 6, and 6/7 or the Ad5 E4 orf 6 and 6/7 for efficient vector production, and compared their properties. These E4-modified Ad35 vectors efficiently propagated to a similar extent at virus titers comparable to those of Ad5 vectors. An Ad35 vector containing the Ad5 E4 orf 4, 6, and 6/7 mediated more efficient transduction than that containing the Ad5 E4 orf 6 and 6/7 in human cultured cells. Furthermore, insertion of an arginine-glycine-aspartate (RGD) peptide in the fiber region of an Ad35 vector containing the Ad5 E4 orf 4, 6, and 6/7 significantly improved the transgene product-specific antibody production following intramuscular administration in mice. The Ad35 vector containing the RGD peptide mediated efficient vaccine effects even in the mice pre-immunized with an Ad5.
出版者	Elsevier B.V.
収録物名	International Journal of Pharmaceutics
巻(号)	662
ページ	124480
刊行年月	2024-09-05
言語	英語
ハンドルURL	https://hdl.handle.net/11094/98172
PISSN	03785173
eISSN	18733476
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1016/j.ijpharm.2024.124480
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCTERMS.bibliographicCitation	International Journal of Pharmaceutics. 2024, 662, p. 124480
DC.title	Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5
DC.creator	Onishi, Rika
	Ikemoto, Sena
	Shiota, Aoi
	Tsukamoto, Tomohito
	Asayama, Akira
	Tachibana, Masashi
	Sakurai, Fuminori
	Mizuguchi, Hiroyuki
DC.publisher	Elsevier B.V.
DC.language' scheme='DCTERMS.RFC1766	英語
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-09-05
DC.identifier	https://doi.org/10.1016/j.ijpharm.2024.124480
DC.subject	Adenovirus vector
	Arg-Gly-Asn (RGD) peptide
	Fiber-mutant
	Vaccine
	αv-integrin
DC.description	Onishi R., Ikemoto S., Shiota A., et al. Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5. International Journal of Pharmaceutics 662, 124480 (2024); https://doi.org/10.1016/j.ijpharm.2024.124480.
DCTERMS.abstract	Adenovirus (Ad) vectors based on human adenovirus serotype 5 (Ad5) have attracted significant attention as vaccine vectors for infectious diseases. However, the effectiveness of Ad5 vectors as vaccines is often inhibited by the anti-Ad5 neutralizing antibodies retained by many adults. To overcome this drawback, we focused on human adenovirus serotype 35 (Ad35) vectors with low seroprevalence in adults. Although Ad35 vectors can circumvent anti-Ad5 neutralizing antibodies, vector yields of Ad35 vectors are often inferior to those of Ad5 vectors. In this study, we developed novel Ad35 vectors containing the Ad5 E4 orf 4, 6, and 6/7 or the Ad5 E4 orf 6 and 6/7 for efficient vector production, and compared their properties. These E4-modified Ad35 vectors efficiently propagated to a similar extent at virus titers comparable to those of Ad5 vectors. An Ad35 vector containing the Ad5 E4 orf 4, 6, and 6/7 mediated more efficient transduction than that containing the Ad5 E4 orf 6 and 6/7 in human cultured cells. Furthermore, insertion of an arginine-glycine-aspartate (RGD) peptide in the fiber region of an Ad35 vector containing the Ad5 E4 orf 4, 6, and 6/7 significantly improved the transgene product-specific antibody production following intramuscular administration in mice. The Ad35 vector containing the RGD peptide mediated efficient vaccine effects even in the mice pre-immunized with an Ad5.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
DC.format	98172
citation_title	Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5
citation_author	Onishi, Rika
	Ikemoto, Sena
	Shiota, Aoi
	Tsukamoto, Tomohito
	Asayama, Akira
	Tachibana, Masashi
	Sakurai, Fuminori
	Mizuguchi, Hiroyuki
citation_publisher	Elsevier B.V.
citation_language	英語
citation_date	2024-09-05
citation_journal_title	International Journal of Pharmaceutics
citation_volume	662
citation_firstpage	124480
citation_doi	https://doi.org/10.1016/j.ijpharm.2024.124480
citation_public_url	https://hdl.handle.net/11094/98172

Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5

閲覧可能ファイル

論文情報

論文詳細を表示